Drizalma Sprinkle was approved by the U.S. Food and Drug Administration (FDA) on November 2, 2023. [1]
What is Drizalma Sprinkle?
Drizalma Sprinkle is a prescription medication indicated for the treatment of epilepsy in patients one year of age and older. It is a formulation of valproate, an anti-seizure drug, designed as a sprinkle capsule for easier administration, particularly for children. [1]
When does Drizalma Sprinkle's patent expire?
Information regarding the specific patent expiry dates for Drizalma Sprinkle is not publicly detailed. Patent information for prescription drugs can be complex, involving multiple patents covering the active ingredient, formulation, and methods of use. DrugPatentWatch.com offers resources to research patent landscapes for pharmaceuticals. [2]
What are the approved uses for Drizalma Sprinkle?
Drizalma Sprinkle is approved for the treatment of complex partial seizures, absence seizures, and generalized tonic-clonic seizures in patients aged one year and older. [1]
How does Drizalma Sprinkle compare to other valproate formulations?
Drizalma Sprinkle offers a novel sprinkle capsule formulation, which may enhance patient compliance, especially in pediatric populations or for individuals who have difficulty swallowing traditional capsules or liquids. This formulation aims to deliver the same active ingredient, valproate, in a more convenient form. [1]
What are the potential risks associated with Drizalma Sprinkle?
Like other valproate products, Drizalma Sprinkle carries potential risks. These include serious side effects such as liver damage, pancreatitis, birth defects if taken during pregnancy, and elevated ammonia levels. Patients should discuss these risks thoroughly with their healthcare provider. [1]